Effects of Single-Dose Atorvastatin on Peri-Procedural Myonecrosis During Percutaneous Coronary Intervention in Patients With Acute Coronary Syndromes - The NO-MI Study.
Phase of Trial: Phase IV
Latest Information Update: 04 Jan 2018
At a glance
- Drugs Atorvastatin (Primary)
- Indications Acute coronary syndromes
- Focus Biomarker; Pharmacodynamics
- Acronyms NO-MI
- 10 Jun 2017 Biomarkers information updated
- 05 Jun 2017 Status changed from not yet recruiting to discontinued.
- 03 Aug 2009 New trial record